← EU Feed

Ethyreal Bio Emerges from Stealth with $101 Million in Financing to Advance ETHY-001, a Potentially Best-in-Class Anti-TSHR Antibody for Thyroid Eye Disease and Graves’ Disease

Source Summary

– ETHY-001 targets the causal pathogenic mechanism underlying both conditions –

Advertisement
Read Original Article